GE HealthCare reports third quarter 2025 financial results

Core Insights - GE HealthCare reported strong financial results for Q3 2025, with robust order growth across all segments driven by customer demand and a healthy capital equipment environment [2][5][6] Financial Performance - Total revenues reached $5.1 billion, marking a 6% increase year-over-year, with organic revenue growth of 4% [5][6] - Net income attributable to GE HealthCare was $446 million, down from $470 million in the prior year, resulting in a net income margin of 8.7% [6][7] - Diluted earnings per share (EPS) were $0.98, a decrease from $1.02 in the previous year, while adjusted EPS was $1.07 compared to $1.14 [5][6][7] - Cash flow from operating activities was $593 million, down $149 million year-over-year, and free cash flow was $483 million, down $168 million [6][7] Segment Performance - Imaging segment revenues were $2.35 billion, up 5% year-over-year, with organic growth of 4% [7][22] - Advanced Visualization Solutions (AVS) revenues increased by 7% to $1.30 billion, with organic growth of 6% [7][22] - Patient Care Solutions (PCS) revenues decreased by 6% to $731 million, with organic revenue down 7% [7][22] - Pharmaceutical Diagnostics (PDx) revenues surged by 20% to $749 million, with organic growth of 10% [7][22] Guidance and Future Outlook - The company raised the lower end of its full-year 2025 adjusted EPS guidance range and reaffirmed other metrics, anticipating continued growth despite tariff impacts [8] - Tariff assumptions include increases on U.S.-China tariffs and other international tariffs, which are expected to affect financial performance [8] Innovation and Strategic Developments - GE HealthCare announced several strategic initiatives, including a 14-year Care Alliance for advanced imaging solutions and the launch of new AI-supported healthcare applications [9] - The company is focused on enhancing its neurology portfolio through acquisitions and partnerships, including the intent to acquire icometrix [9]